Summary & Overview
CPT 90674: Quadrivalent Cell-Derived Influenza Vaccine
CPT code 90674 identifies a cell-derived, quadrivalent influenza vaccine administered as a 0.5 mL intramuscular injection. The product contains no preservatives or antibiotics and protects against four influenza strains, making it a key preventive service during seasonal influenza periods. Nationally, this vaccine code matters for immunization programs, payer coverage policies, and public health vaccination efforts.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for this vaccine, typical sites of service, and the common modifiers associated with vaccine billing. The publication summarizes benchmarks and payer coverage patterns, highlights relevant coding considerations for outpatient immunization delivery, and notes where input data was not provided.
This summary is intended for clinicians, billing professionals, and policy analysts seeking concise information on CPT code 90674, its clinical role in influenza prevention, and the payer landscape relevant to national immunization billing practices.
Billing Code Overview
CPT code 90674 describes a quadrivalent influenza vaccine derived from cell cultures. The product protects against four strains of influenza, is preservative- and antibiotic-free, and is provided as a 0.5 mL intramuscular injection.
-
Service type: Immunization vaccine administration (quadrivalent, cell-derived influenza vaccine)
-
Typical site of service: Ambulatory clinic, physician office, public health clinic, pharmacy immunization area, or other outpatient settings where intramuscular vaccines are administered.
Clinical & Coding Specifications
Clinical Context
A 45-year-old adult presents to a primary care clinic during influenza season requesting routine immunization. The patient has no acute febrile illness, no history of severe allergic reaction to prior influenza vaccines or vaccine components, and is eligible for standard intramuscular influenza vaccination. After verbal consent and vaccine screening, a clinician prepares a 0.5 mL dose of the cell culture–derived, quadrivalent influenza vaccine and administers it intramuscularly into the deltoid. Documentation includes vaccine product lot number, expiration date, manufacturer, route (IM), dose (0.5 mL), anatomical site, informed consent, and any observed immediate adverse reactions. Billing is submitted using 90674 with appropriate modifiers when relevant (for example, modifier 00 for unaltered service, 25 if a significant separate evaluation is provided on the same date, or QY/QZ when billing for a vaccine under an administration program). Typical sites of service are outpatient primary care clinics, occupational health clinics, retail pharmacy clinics, community health centers, and employer-sponsored health events.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|